Talnetant

Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several functions (primarily treatment of irritable bowel syndrome, despite a 2007 study finding no statistically significant improvement in rectal hypersensitivity over placebo). Its use as a potential antipsychotic drug for the treatment of schizophrenia has also been discontinued.^[1][2][3][4]

Talnetant

Clinical data
ATC code	none
Identifiers
IUPAC name 3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
CAS Number	174636-32-9 Y
PubChem CID	133090
IUPHAR/BPS	2124
ChemSpider	117450 N
UNII	CZ3T9T146K
ECHA InfoCard	100.236.526
Chemical and physical data
Formula	C25H22N2O2
Molar mass	382.463 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCC(C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)O
InChI InChI=1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29) N Key:BIAVGWDGIJKWRM-UHFFFAOYSA-N N
NY (what is this?)  (verify)

See also

• Tachykinin receptor 3 § Agonists